吉林敖東(000623.SZ):截止2022年末,吉林敖東大藥房連鎖共開設187家連鎖藥店
格隆匯6月20日丨吉林敖東(000623.SZ)近期在接待機構調研時表示,連鎖藥店批發和零售是公司醫藥板塊三大主要業務之一,截止2022年末,子公司吉林敖東大藥房連鎖有限公司共開設187家連鎖藥店,營業收入增幅較大,較上年同期增長80.45%,主要原因在於自2022年3月起吉林敖東大藥房連鎖有限公司主要負責藥品終端的配送業務,藥房連鎖承擔了相關物資的配送及其他相關服務,藥房連鎖同時開拓了吉大一院等醫院的醫療器械配送業務,這使得公司上半年度批發、零售業務同比有較快的增速。所以公司下達2023年扣除相關物資供應外要求確保同比完成20%以上的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.